Iovance BIOTHERAPEUTICS, Inc. (IOVA) intrinsic value & 10-year financials
Iovance BIOTHERAPEUTICS, Inc. (IOVA) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 1388.7% a year to $263.5M, with an average return on invested capital of -61.9%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $13.62
- Market cap
- $4.9M
- Revenue (FY2025)
- $263.5M
- Revenue growth (10-yr CAGR)
- 1388.7%
- ROIC (10-yr avg)
- -61.9%
- Free cash flow (FY2025)
- -$336.2M
IOVA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $263.5M | -$391.0M | -$1.09 | -$336.2M | -153.1% | -65.7% |
| FY2024 | $164.1M | -$372.2M | -$1.28 | -$364.0M | -240.9% | -66.6% |
| FY2023 | $1.2M | -$444.0M | -$1.89 | -$384.1M | -38735.0% | -104.0% |
| FY2022 | — | -$395.9M | -$2.49 | -$313.2M | — | -83.9% |
| FY2021 | — | -$342.3M | -$2.23 | -$265.5M | — | -55.1% |
| FY2020 | — | -$259.6M | -$1.88 | -$251.9M | — | -56.7% |
| FY2019 | — | -$197.6M | -$1.59 | -$165.8M | — | -61.5% |
| FY2018 | $0 | -$123.6M | — | -$102.4M | — | -33.4% |
| FY2017 | $0 | -$92.1M | — | -$79.7M | — | -59.5% |
| FY2016 | $0 | -$52.9M | — | -$34.2M | — | -32.1% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
IOVANCE BIOTHERAPEUTICS, INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
IOVANCE BIOTHERAPEUTICS, INC. has historically struggled to out-earn its cost of capital, averaging just -65.9% ROIC.
IOVANCE BIOTHERAPEUTICS, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, IOVANCE BIOTHERAPEUTICS, INC. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-36.21 per share.